Company intelligence / Profile preview
ProteoTech
Kirkland, Washington, United Statesproteotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Exebryl-1(R) entered Phase 1 clinical trials in 2008 for Alzheimer's disease, showing preclinical efficacy in reducing beta-amyloid load by 30-50% and improving memory in transgenic mice; also potential tau inhibition.
- Therapeutic areas
- EndocrinologyNeurologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on ProteoTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProteoTech.